Hypertension promotes islet morphological changes with vascular injury on pre-diabetic status in SHRsp rats

References

• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–44
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–91
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963–9
   PubMed Web of Science ®Google Scholar
• Ogihara T, Nakao K, Fukui T, et al. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res 2008;31:1595–601
   PubMed Web of Science ®Google Scholar
• Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003;41:431–6
   PubMed Web of Science ®Google Scholar
• Hughes DB, Britton ML. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Pharmacotherapy 2005;25:1602–20
   PubMed Web of Science ®Google Scholar
• Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46:821–6
   PubMed Web of Science ®Google Scholar
• Scheen AJ. VALUE: analysis of results. Lancet 2004;364:932–3; author reply 935
   PubMed Web of Science ®Google Scholar
• Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol (Copenh) 1967;55:330–45
   PubMedGoogle Scholar
• Yamori Y, Tomimoto K, Ooshima A, et al. Proceedings: developmental course of hypertension in the SHR-substrains susceptible to hypertensive cerebrovascular lesions. Jpn Heart J 1974;15:209–10
   PubMedGoogle Scholar
• Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963;27:282–93
   PubMedGoogle Scholar
• Nagasu H, Satoh M, Kuwabara A, et al. Overexpression of klotho protein modulates uninephrectomy-induced compensatory renal hypertrophy by suppressing IGF-I signals. Biochem Biophys Res Commun 2011;407:39–43
   PubMed Web of Science ®Google Scholar
• Hayden MR, Sowers JR. Isletopathy in Type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress. Antioxid Redox Signal 2007;9:891–910
   PubMed Web of Science ®Google Scholar
• Nagasu H, Satoh M, Fujimoto S, et al. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity. Hypertens Res 2012;35:348–55
   PubMed Web of Science ®Google Scholar
• Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102–10
   PubMed Web of Science ®Google Scholar
• Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787–94
   PubMed Web of Science ®Google Scholar
• Yokota T, Denham W, Murayama K, et al. Pancreatic stellate cell activation and MMP production in experimental pancreatic fibrosis. J Surg Res 2002;104:106–11
   PubMed Web of Science ®Google Scholar
• Haber PS, Keogh GW, Apte MV, et al. Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. Am J Pathol 1999;155:1087–95
   PubMed Web of Science ®Google Scholar
• Fliser D, Schaefer F, Schmid D, et al. Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. Hypertension 1997;30:1156–61
   PubMed Web of Science ®Google Scholar
• Santoro D, Natali A, Palombo C, et al. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 1992;20:181–91
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868–73
   PubMed Web of Science ®Google Scholar
• Ardiansyah, Shirakawa H, Sugita Y, et al. Anti-metabolic syndrome effects of adenosine ingestion in stroke-prone spontaneously hypertensive rats fed a high-fat diet. Br J Nutr 2010;104:48–55
   PubMed Web of Science ®Google Scholar
• Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001;88:E14–22
   PubMed Web of Science ®Google Scholar
• Satoh M, Fujimoto S, Haruna Y, et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005;288:F1144–52
   PubMed Web of Science ®Google Scholar
• Mohan S, Reddick RL, Musi N, et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest 2008;88:515–28
   PubMedGoogle Scholar
• Kuwabara A, Satoh M, Tomita N, et al. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia 2010;53:2056–65
   PubMed Web of Science ®Google Scholar
• Nagasu H, Satoh M, Yorimitsu D, et al. Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats. Kidney Blood Press Res 2011;34:87–96
   PubMed Web of Science ®Google Scholar
• Ko SH, Kwon HS, Kim SR, et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun 2004;316:114–22
   PubMedGoogle Scholar
• Dong YF, Liu L, Kataoka K, et al. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 2010;53:180–91
   PubMed Web of Science ®Google Scholar